alexa
Reach Us +44-1235425476
Bone-Seeking Targeted Radio-Nuclide Therapy BT-RNT) in Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC): Shifting from Palliation to Improving Survival | Abstract
ISSN: 2155-9619

Journal of Nuclear Medicine & Radiation Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Bone-Seeking Targeted Radio-Nuclide Therapy BT-RNT) in Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC): Shifting from Palliation to Improving Survival

Vimoj J Nair1, Colin Malone2, Patricia Moretto3, Eugene Leung3 and Shawn Malone1*

1Division of Radiation Oncology, University of Ottawa and Ottawa Hospital, Ottawa, Canada

2Division of Medical Oncology, University of Ottawa and Ottawa Hospital, Ottawa, Canada

3Division of Nuclear Medicine, University of Ottawa and Ottawa Hospital, Ottawa, Canada

*Corresponding Author:
Shawn Malone
Associate Professor, Department of Radiation Oncology
The Ottawa Hospital Cancer Centre, 501 Smyth Road
Ottawa, Ontario, K1H 8L6, Canada
Tel: 001-613-737-7700
E-mail: [email protected]

Received date: October 16, 2014; Accepted date: November 28, 2014; Published date: December 01, 2014

Citation: Nair VJ, Malone C, Moretto P, Leung E, Malone S (2014) Bone-Seeking Targeted Radio-Nuclide Therapy (BT-RNT) in Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC): Shifting from Palliation to Improving Survival. J Nucl Med Radiat Ther 5:202. doi:10.4172/2155-9619.1000202

Copyright: © 2014 Nair VJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: The purpose of this article is to review the role of bone-seeking targeted radionuclide therapy (BT-RNT) in metastatic prostate cancer. The mechanisms of actions, radiobiology and clinical benefits of BT-RNTs will be reviewed.

Methods: Relevant studies of CRPC and targeted therapies were identified from literature and clinical trial databases, websites, and conference abstracts.

Results: BT-RNT in mCRPC has a proven beneficial palliative role in treatment of patients with mCRPC. The use of these agents as a monotherapy as well as combination with other palliative therapies are evolving. Among the various BT-RNT’s the alpha emitter 223Ra which is highly targeted and well tolerated has shown significant clinical benefit and survival advantage in this patient population.

Conclusion: BT-RNT represents an exciting treatment option for patients with mCRPC. 223Ra represents a new treatment paradigm for patients with mCRPC.

Keywords

Recommended Conferences

Clinical Oncology & Radiation Therapy

Singapore, Singapore
Share This Page
Top